RNAi Roundtable: HTT02 - ALNYLAM PHARMACEUTICALS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed as Alnylam is presenting early-stage clinical data (Phase 1b) for a single investigational asset rather than quarterly results.
• The company highlighted its status as a biotech with six approved medicines and a pipeline of over 25 programs, positioning the RNAi platform as a driver for future long-term growth toward "Alnylam 2030" goals.
• No revenue guidance is provided for Brezosiran, which remains in clinical development.

Guidance and Future Outlook:

• Clinical Timeline: Planning to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment.
• Study Design: The pivotal trial is expected to be a several-year duration study using established clinical endpoints (e.g., UHDRS, TFC) to definitively test efficacy.
• Open-Label Extension (OLE): Ongoing Phase 1b OLE will allow for dosing every six months to gather long-term safety and exploratory efficacy data over 24–36 months.
• Strategic Goal: To establish proof of concept for the Exon 1 targeting strategy (lowering both full-length and HTT1A isoforms) and to demonstrate durable, deep knockdown in the CNS.

Business Segments and Product Lines:

• Brezosiran (ALN-HTT1A): Investigational RNAi therapeutic for Huntington's disease (HD) targeting the first exon of the HTT gene.
• Target Strategy: Exon 1 targeting designed to lower all mutant HTT species, including the full-length protein and the shorter, highly toxic HTT1A isoform, which many competitors miss.
• Platform: Utilizes the C16-S RNA delivery platform for intrathecal administration, enabling robust biodistribution across the CNS (striatum, cortex) and deep brain tissues.
• Pipeline Expansion: C16-S platform success is enabling a broader CNS pipeline in collaboration with Regeneron (Alzheimer's, ALS, Parkinson's).

Market and Competitive Landscape:

• Unmet Need: Estimates ~100,000 symptomatic patients globally (~33,000 in the U.S.) with no approved disease-modifying therapies.
• Competitive Differentiation: Unlike other candidates (e.g., Tofersen, WVE003) that target downstream exons and failed to lower HTT1A or showed safety signals (elevated neurofilament light chain/NfL), Brezosiran aims to address the full spectrum of toxic species.
• Market Opportunity: Market size expected to expand as patients become more willing to undergo genetic testing once effective therapies are anticipated, moving beyond the current ~33,000 diagnosed patients to include undiagnosed gene carriers.

Risks and Challenges:

• Measurement Challenges: Difficulty in detecting and quantifying the HTT1A isoform in clinical samples (CSF) due to low abundance and aggregation, requiring reliance on surrogate markers (full-length HTT knockdown).
• Safety Uncertainties: While current data is encouraging, the optimal threshold for HTT lowering (efficacy vs. safety) is not yet established; concerns exist regarding potential neuronal injury (NfL elevation) or CNS inflammation (ventricular enlargement, WBC/protein in CSF).
• Administration: Reliance on intrathecal injection; while deemed acceptable for this indication, the need for invasive procedures remains a consideration for future chronic therapy adoption.
• Regulatory Path: Pivotal trial design and endpoints require ongoing alignment with regulators; accelerated approval based on natural history comparisons is uncertain at this stage.

Management Commentary and Tone:

• Tone: Highly confident and optimistic, emphasizing the "differentiated" nature of the Exon 1 strategy and the robustness of the C16-S platform.
• Key Message: Management asserts that the "sweet spot" for safety is likely around 50% lowering (supported by human genetics and primate data) and that their data shows no safety signals even at deep knockdown levels.
• Urgency: Strong emphasis on the urgency of the disease and the potential to intervene early, citing patient stories to underscore the emotional and clinical need.

Analyst Questions and Answers:

• Optimal Knockdown Level: Dr. Bates and Kevin Sloan indicated ~50% lowering appears optimal based on preclinical data (mice) and human heterozygous loss data; 90-95% is not deemed necessary.
• HTT1A Quantification: Confirming that while HTT1A is difficult to measure directly in CSF, the Exon 1 strategy ensures simultaneous lowering of full-length and HTT1A; preclinical data supports this equivalence.
• Dosing and Biodistribution: Dose escalation is driven by the need to achieve deep knockdown in deep brain structures (striatum), not just CSF; CSF levels serve as a proxy but tissue levels are the true target.
• Wild-Type Safety: Non-human primate studies (up to 12 months, >90% knockdown) showed no adverse effects, supporting the safety of wild-type lowering in adult settings.
• Administration Route: Intrathecal is the current priority; brain shuttle platforms are in development but not required for initial proof of concept.
• Timing: Earlier intervention is likely more effective based on mouse models, but the exact "point of no return" in humans remains unknown.

Other Key Points:

• Preclinical Validation: Dr. Jill Bates presented three recent studies (2024) demonstrating that targeting HTT1A alone or with full-length HTT significantly reduces aggregation and improves transcriptional dysregulation in mouse models, often outperforming full-length targeting alone.
• Biomarker Safety: Initial Phase 1b data showed no increase in CSF neurofilament light chain (NfL), no dose-dependent ventricular enlargement, and no CNS inflammatory markers (WBC/protein) compared to placebo.
• Pharmacology: Single intrathecal dose resulted in 60-64% mean CSF mutant HTT reduction (up to 83% in individuals) at 3 months; durability and peak efficacy in deep tissue tissues are still being evaluated.
• Patient Advocacy: Strong emphasis on partnership with the HD community, citing the story of patient Alyssa to illustrate the need for disease-modifying therapies.